The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed strong Phase 2 results in relapsed/refractory AML, surpassing 20% overall ...

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies. Management of newly diagnosed acute ...

Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an ...

Ligufalimab targets CD47, enhancing macrophage-mediated cancer cell destruction, and avoids red blood cell clumping, improving safety and efficacy. Early trials show ligufalimab, combined with Vidaza ...

Patients with acute myeloid leukemia (AML) in remission for 3 years have survival rates similar to the general population, but long-term needs remain poorly understood. A retrospective analysis showed ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...

Secondary POLE Mutation Drives Metastasis in Hereditary Breast and Ovarian Cancer: Revealing Fallopian Tube Ultramutation This is a case report of individualized therapy for DDX41-mutated AML. The ...

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...